Regeneron: brands it owns and its ownership tree
Regeneron (NASDAQ: REGN) is a publicly listed company headquartered in Tarrytown, United States that owns 8 consumer brands.[1]
Regeneron is a US biotechnology company based in Tarrytown, New York. Its 2025 Form 10-K reports net product sales of Eylea, Libtayo, Praluent and other medicines, and collaboration revenue from Sanofi, Bayer and others.
-
brands owned
-
1
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Regeneron Pharmaceuticals, Inc.
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇺🇸 Tarrytown, United States
- Founded
- 1988
- Tickers
- NASDAQ: REGN
- SEC CIK
- 0000872589
- Last verified
- · 1 sources
Regeneron in numbers
- Regeneron owns 8 consumer brands tracked here across 1 top-level categories; the largest is healthcare & pharma with 8 brands.[1]
Regeneron financial history
Headline figures from Regeneron's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $8.5bn to $14.3bn, an average of 11.0% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $14.3bn | $3.58bn | 24.9% | $4.5bn | $40.6bn | $1.99bn | 10-K | |
| $14.2bn | $3.99bn | 28.1% | $4.41bn | $37.8bn | $1.98bn | 10-K | |
| $13.1bn | $4.05bn | 30.9% | $3.95bn | $33.1bn | $1.98bn | 10-K | |
| $12.2bn | $4.74bn | 38.9% | $4.34bn | $29.2bn | $1.98bn | 10-K | |
| $16.1bn | $8.95bn | 55.7% | $8.08bn | $25.4bn | $1.98bn | 10-K | |
| $8.5bn | $3.58bn | 42.1% | $3.51bn | $17.2bn | $1.98bn | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Everything Regeneron owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree → · Download as infographic
Brand portfolio by category
Recent changes to this record
Regeneron in the global legal-entity registry
The Global Legal Entity Identifier Foundation (GLEIF) keeps an open register of legal entities. Each entity reports its own parents. We show it as a cross-check on the ownership recorded on this page, which is built from filings.
- Legal entity identifier (LEI)
- 549300RCBFWIRX3HYQ56
- Registered name
- REGENERON PHARMACEUTICALS, INC. (US)
- Registration status
- Issued · record updated 24 November 2025
- Parent
- None named: it reports that no person or entity controls it.
- Retrieved
- · GLEIF record (JSON)
Regeneron SEC filings
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
Annual reports
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
Proxy statements
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
Recent current and quarterly reports
| Filed | Form | What it declares |
|---|---|---|
| 8-K | Entry into a material agreement; Results of operations and financial condition; Other events | |
| 8-K | Departure or appointment of directors or officers | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of a shareholder vote | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition; Regulation FD disclosure | |
| 10-Q | Quarterly report | |
| 8-K | Results of operations and financial condition | |
| 8-K | Results of operations and financial condition |
Official recalls involving Regeneron products
3 recall notices from government regulators matched to Regeneron. Each applies to the specific products, sizes and lot codes named in the notice, not to every product sold under the name.
- Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron… — FDA, · Class II
Reason given: Lack of Assurance of Sterility
Recalling firm: Regeneron Pharmaceuticals Inc · Brand: Libtayo
- EYLEA, (aflibercept) Injection, For Intravitreal injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Glass Syringe, Rx only, Manufactured… — FDA, · Class II
Reason given: Lack of Assurance of Sterility: Complaints of syringe breakage
Recalling firm: Regeneron Pharmaceuticals Inc · Brand: Eylea
- EYLEA, (aflibercept) Injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals,… — FDA, · Class II
Reason given: Lack of Assurance of Sterility: Complaints of syringe breakage
Recalling firm: Regeneron Pharmaceuticals Inc · Brand: Eylea
Matched automatically from FDA, USDA FSIS, UK Food Standards Agency and CPSC records only when the recalling firm corresponds to this ownership record and, for a brand, the brand name appears in the product description. Check the linked notice for exact products and lots. Method.
Frequently asked questions
What brands does Regeneron own?
Regeneron owns 8 consumer brands tracked here, including Lynozyfic, Praluent, Evkeeza, Inmazeb, Libtayo and Zaltrap.
Is Regeneron an American company?
Yes. Regeneron is headquartered in Tarrytown, United States and was founded in 1988.
Who owns Regeneron?
Regeneron is a publicly listed company owned by its shareholders; it trades as REGN on the NASDAQ.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Regeneron Pharmaceuticals, Inc. Annual Report on Form 10-K filed 2026-02-04 — SEC EDGAR, SEC Form 10-K, published 4 February 2026; retrieved 16 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.